Inhibitors of LRRK2 kinase activity to probe the treatment option in Parkinson's disease.
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland. jarkko.t.rautio@uef.fi
Jarkko
J
Rautio
D006801:Humans; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D058990:Molecular Targeted Therapy; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
D047428:Protein Kinase Inhibitors; C495280:LRRK2 protein, human; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D017346:Protein Serine-Threonine Kinases